bitopertin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
051020122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
PURPOSE/BACKGROUND Deficits in N-methyl-D-aspartate receptor (NMDAR) function contribute to symptoms and cognitive dysfunction in… (More)
Is this relevant?
2017
2017
BACKGROUND There is currently no standard of care for treatment of negative symptoms of schizophrenia, although some previous… (More)
Is this relevant?
2016
2016
OBJECTIVE To assess the effect of strong and moderate cytochrome P450 (CYP) 3A4 inhibition on exposure of bitopertin, a glycine… (More)
Is this relevant?
2016
2016
BACKGROUND Bitopertin, a glycine reuptake inhibitor, was investigated as a novel treatment for schizophrenia. We report all the… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
IMPORTANCE In schizophrenia, the severity of negative symptoms is a key predictor of long-term disability. Deficient signaling… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2014
2014
In this issue, Umbricht and colleagues1 reported improvement of negative symptomsof schizophrenia associatedwith 2 of 3 doses of… (More)
Is this relevant?
2014
2014
Bitopertin is a glycine reuptake inhibitor postulated to improve N-methyl-d-aspartate receptor hypofunction by increasing… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
Deficient N-methyl-D-aspartate (NMDA) receptor transmission is thought to underlie schizophrenia. An approach for normalizing… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
BACKGROUND Bitopertin (RG1678) is a glycine reuptake inhibitor currently in phase 3 trials for treatment of schizophrenia. This… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2012
2012
BACKGROUND Bitopertin (RG1678) is a selective glycine reuptake inhibitor currently in Phase III development for the treatment of… (More)
Is this relevant?